ATE375168T1 - Die synergistischen wirkungen von hgf und antibakterieller behandlung - Google Patents

Die synergistischen wirkungen von hgf und antibakterieller behandlung

Info

Publication number
ATE375168T1
ATE375168T1 AT01963646T AT01963646T ATE375168T1 AT E375168 T1 ATE375168 T1 AT E375168T1 AT 01963646 T AT01963646 T AT 01963646T AT 01963646 T AT01963646 T AT 01963646T AT E375168 T1 ATE375168 T1 AT E375168T1
Authority
AT
Austria
Prior art keywords
hgf
synergistic effects
antibacterial treatment
ongoing
septicaemia
Prior art date
Application number
AT01963646T
Other languages
English (en)
Inventor
Fariba Nayeri
Original Assignee
Damavand Wound Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003038A external-priority patent/SE0003038L/xx
Priority claimed from SE0101823A external-priority patent/SE0101823D0/xx
Application filed by Damavand Wound Ab filed Critical Damavand Wound Ab
Application granted granted Critical
Publication of ATE375168T1 publication Critical patent/ATE375168T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01963646T 2000-08-28 2001-08-28 Die synergistischen wirkungen von hgf und antibakterieller behandlung ATE375168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0003038A SE0003038L (sv) 2000-08-28 2000-08-28 Synergieffekter av HGF och antibakteriell behandling
SE0101823A SE0101823D0 (sv) 2001-05-21 2001-05-21 Analysis of excrement with regard to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
ATE375168T1 true ATE375168T1 (de) 2007-10-15

Family

ID=26655219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963646T ATE375168T1 (de) 2000-08-28 2001-08-28 Die synergistischen wirkungen von hgf und antibakterieller behandlung

Country Status (7)

Country Link
US (2) US7601365B2 (de)
EP (3) EP1320384B1 (de)
AT (1) ATE375168T1 (de)
AU (1) AU2001284576A1 (de)
DE (1) DE60130906T2 (de)
ES (1) ES2295198T3 (de)
WO (1) WO2002017964A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
US20060199762A1 (en) * 2003-09-03 2006-09-07 Toshikazu Nakamura Skin ulcer preventive curative agent containing human recombinant hgf
DE602004019134D1 (de) * 2003-09-29 2009-03-05 Peas Inst Ab Schnelle bestimmung verschiedener formen von hgf (heptocyte growth factor) in den körperflüssigkeiten
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
US20090068179A1 (en) * 2005-11-16 2009-03-12 Fariba Nayeri Methods for Inhibiting Carcinogenesis and/or Metastasis in an Individual with Endogenous C-Met Ligands and Inhibitors
WO2011028173A1 (en) * 2009-09-05 2011-03-10 Fariba Nayeri Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection
SE536400C2 (sv) 2012-02-22 2013-10-08 Peas Inst Ab Ny metod för snabb detektion av hepatocyttillväxtfaktor i biologiska vätskor
RU2597780C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2597781C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2716713C1 (ru) * 2019-08-01 2020-03-16 Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук Способ диагностики стадии острого пиелонефрита

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176347A (en) * 1876-04-18 Improvement in filling packages with comb-honey
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
JP2750372B2 (ja) 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JPH083195A (ja) 1991-10-04 1996-01-09 Toshiichi Nakamura 組織傷害治癒因子
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
WO1994004175A1 (fr) 1992-08-24 1994-03-03 Toshikazu Nakamura Promoteur de la production du facteur de croissance des hepatocytes
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
JP3477832B2 (ja) 1994-07-22 2003-12-10 三菱化学株式会社 肝疾患の検出方法
US5656443A (en) * 1994-07-29 1997-08-12 Long Island Jewish Medical Center Method of diagnosing bladder cancer
JP3737532B2 (ja) 1994-08-19 2006-01-18 敏一 中村 軟骨障害治療剤
US6756358B2 (en) * 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
ATE257844T1 (de) * 1995-03-10 2004-01-15 Nakamura Toshikazu Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
JPH08268907A (ja) 1995-03-31 1996-10-15 Sunstar Inc 歯周組織再生促進剤
CA2224253A1 (en) 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
KR100765687B1 (ko) 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
WO1997009997A1 (en) * 1995-09-12 1997-03-20 Genentech, Inc. Cystic fibrosis therapy
JP3832674B2 (ja) 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
JP4463885B2 (ja) 1996-12-05 2010-05-19 敏一 中村 劇症肝炎疾患治療剤
JP4865936B2 (ja) 1997-03-15 2012-02-01 中村 敏一 急性腎不全治療用ｈｇｆ
CA2218145C (en) * 1997-04-14 2008-01-08 Toshikazu Nakamura Method of treating dilated cardiomyopathy
EP1074264B1 (de) 1998-04-28 2008-09-17 Toshikazu Nakamura Inhibitoren für die gefässneubildung
EP1242451A2 (de) * 1999-12-15 2002-09-25 EntreMed, Inc. Zusammensetzung und verfahren zur hemmung der proliferation von endothelzellen
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤

Also Published As

Publication number Publication date
WO2002017964A1 (en) 2002-03-07
US7601365B2 (en) 2009-10-13
EP1867996A1 (de) 2007-12-19
DE60130906T2 (de) 2008-07-17
US20040042968A1 (en) 2004-03-04
ES2295198T3 (es) 2008-04-16
EP1320384A1 (de) 2003-06-25
US20100160223A1 (en) 2010-06-24
DE60130906D1 (de) 2007-11-22
EP1840575A1 (de) 2007-10-03
EP1320384B1 (de) 2007-10-10
AU2001284576A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
DE60119939D1 (de) Chinolinderivate als antibakterielle mittel
DK1284740T3 (da) Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
DE68917163D1 (de) Antibakterielle Mittel.
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
ATE326525T1 (de) Bifidobakterium zur behandlung von entzündungskrankheiten
EA200201214A1 (ru) Замещенные тиоацетамиды
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
DE60111757D1 (de) 3-(heteroarylacetamido)-2-oxo-azetidin-1-sulfonsäure derivate als antibakterielle mittel
ATE344799T1 (de) Piperidinderivate als antibakterielle mittel
TNSN03121A1 (en) Formes cristallines d'azithromycine
CY2011012I2 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
TR200400072T4 (tr) Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
SE0102315D0 (sv) Compounds
DE69636228D1 (de) Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
EP1390029A4 (de) Phenylindole zur behandlung von hiv
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE60130906D1 (de) Die synergistischen wirkungen von hgf und antibakterieller behandlung
MA28613B1 (fr) Macrocycles d'amide antibacteriens
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
MA26289A1 (fr) Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales
DE60112581D1 (de) Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten
DE60142958D1 (de) Verwendung von retinoid-typ verbindungen als antibakterielle mittel gegen staphylococcus aureus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320384

Country of ref document: EP